KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Equity Ratio (2009 - 2026)

Gilead Sciences posted quarterly Equity Ratio of 0.42 for Q1 2026, up 23.6% year-on-year from 0.34 in Q1 2025, and up 8.63% on a QoQ basis from 0.38 in Q4 2025.

Gilead Sciences (GILD) has 18 years of Equity Ratio data on file, last reported at 0.42 in Q1 2026.

  • For the quarter ending Q1 2026, Equity Ratio rose 23.6% year-over-year to 0.42; the trailing twelve-month figure through Mar 2026 stood at 0.42 (up 23.6% YoY), and the FY2025 full-year result was 0.38, up 17.91% from the prior year.
  • Equity Ratio for Q1 2026 stood at 0.42, up from 0.38 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.42 in Q1 2026 and bottomed at 0.31 in Q1 2024.
  • The 5-year median for Equity Ratio is 0.34 (2023), against an average of 0.35.
  • The widest annual swing landed in 2024, when Equity Ratio dropped 10.91%; it then increased 23.6% in 2026.
  • A 5-year view of Equity Ratio shows it stood at 0.34 in 2022, then grew by 9.07% to 0.37 in 2023, then fell by 10.91% to 0.33 in 2024, then advanced by 17.91% to 0.38 in 2025, then advanced by 8.63% to 0.42 in 2026.
  • The last three Equity Ratio figures came in at 0.42 (Q1 2026), 0.38 (Q4 2025), and 0.37 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Ratio (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 0.27
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 0.40
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -0.05
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 0.36
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 0.10
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 0.42
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 0.43
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 0.23
10 Gsk 88.34 Bn 83.66 Bn - 0.27

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.42
Dec 31, 2025 0.38
Sep 30, 2025 0.37
Jun 30, 2025 0.35
Mar 31, 2025 0.34
Dec 31, 2024 0.33
Sep 30, 2024 0.34
Jun 30, 2024 0.34
Mar 31, 2024 0.31
Dec 31, 2023 0.37
Sep 30, 2023 0.36
Jun 30, 2023 0.34
Mar 31, 2023 0.34
Dec 31, 2022 0.34
Sep 30, 2022 0.34
Jun 30, 2022 0.32
Mar 31, 2022 0.32
Dec 31, 2021 0.31
Sep 30, 2021 0.32
Jun 30, 2021 0.29
Mar 31, 2021 0.28
Dec 31, 2020 0.27
Sep 30, 2020 0.29
Jun 30, 2020 0.32
Mar 31, 2020 0.37
Dec 31, 2019 0.37
Sep 30, 2019 0.35
Jun 30, 2019 0.36
Mar 31, 2019 0.35
Dec 31, 2018 0.34
Sep 30, 2018 0.36
Jun 30, 2018 0.33
Mar 31, 2018 0.32
Dec 31, 2017 0.29
Sep 30, 2017 0.38
Jun 30, 2017 0.38
Mar 31, 2017 0.35
Dec 31, 2016 0.34
Sep 30, 2016 0.30
Jun 30, 2016 0.32
Mar 31, 2016 0.29
Dec 31, 2015 0.37
Sep 30, 2015 0.34
Jun 30, 2015 0.42
Mar 31, 2015 0.45
Dec 31, 2014 0.46
Sep 30, 2014 0.48
Jun 30, 2014 0.53
Mar 31, 2014 0.48
Dec 31, 2013 0.52
Sep 30, 2013 0.48
Jun 30, 2013 0.49
Mar 31, 2013 0.47
Dec 31, 2012 0.45
Sep 30, 2012 0.41
Jun 30, 2012 0.39
Mar 31, 2012 0.37
Dec 31, 2011 0.40
Sep 30, 2011 0.49
Jun 30, 2011 0.48
Mar 31, 2011 0.48
Dec 31, 2010 0.53
Sep 30, 2010 0.50
Mar 31, 2010 0.70
Dec 31, 2009 0.67
Sep 30, 2009 0.63
Jun 30, 2009 0.63